Home/Pipeline/Oxtellar XR®

Oxtellar XR®

Epilepsy

Approved/CommercialMarketed

Key Facts

Indication

Epilepsy

Phase

Approved/Commercial

Status

Marketed

Company

Supernus Pharmaceuticals

About Supernus Pharmaceuticals

Supernus Pharmaceuticals is a commercial-stage biopharma leader in CNS disorders, leveraging deep expertise in drug delivery and product development to build a diversified portfolio. The company has demonstrated consistent growth, earning recognition on lists like Forbes' America's Best Small Companies and Fortune's 100 Fastest Growing Companies. With a foundation of marketed products generating revenue, Supernus is strategically advancing mid- and late-stage pipeline candidates while maintaining a patient-centric culture and operational excellence.

View full company profile

Therapeutic Areas

Neurology Psychiatry Central Nervous System (CNS)

Other Epilepsy Drugs

Drug	Company	Phase	Status
Soticlestat (TAK-935)	Takeda Pharmaceutical	Phase 3	Active
UCB4144	UCB	Phase 2	Active
Keppra (levetiracetam)	UCB	Approved	Commercial
NBI-921352	Neurocrine Biosciences	Phase 2	Active
ADX71149	Addex Therapeutics	Phase 2	Active (Partner-led)
Motpoly XR™	Aucta Pharmaceuticals	Not Specified (Likely Phase 3/NDA)	Active
ADB-104	Adolore BioTherapeutics	Pre-clinical	Active